Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 2.926000
forwardPE 27.260962
debtToEquity 5.698000
earningsGrowth 0.206000
revenueGrowth 0.141000
grossMargins 0.757480
operatingMargins 0.240680
trailingEps 77.900000
forwardEps 99.280000

AJANTPHARM's current ratio of 2.926 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, AJANTPHARM can comfortably cover its liabilities, reflecting a strong financial outlook.
AJANTPHARM's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
AJANTPHARM's positive earnings and revenue growth indicate that the company is expected to continue expanding its business. These trends reflect strong financial health, with increasing profits and sales suggesting sustained growth and success for AJANTPHARM.
Ajanta Pharma Limited's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
Ajanta Pharma Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Ajanta Pharma Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Price projections for AJANTPHARM have been revised lower over time, signaling a more cautious outlook from analysts. The gradual downward trend indicates that expectations for the company's growth may be softening.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


Ajanta Pharma Limited experienced 9 sell transactions with market price of 2818.4833170572915 per share.Throughout the period under consideration, no sell transactions were recorded.An increase in buying activity relative to selling at AJANTPHARM's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Recent analysis shows a strong buy bias for AJANTPHARM, encouraging investors to view it as a solid investment option. The positive sentiment surrounding AJANTPHARM suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.